AKEBIA THERAPEUTICS, INC. Amortization of Debt Issuance Costs
AKEBIA THERAPEUTICS, INC. (AKBA) reported Amortization of Debt Issuance Costs of $81.25 thousand for the 85-month period ending 2014-03-31, per its 10-Q filed 2014-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2016-03-14
- AKEBIA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-12-31 was $4.00K.
- AKEBIA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-09-30 was -$747.88K.
- AKEBIA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-06-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2013-03-31 was $751.88K.
- AKEBIA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2013 was $8.00K, a 52.94% decline from fiscal 2012.
- AKEBIA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2012 was $17.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 85 month |
|---|---|---|---|---|---|
| 2014-03-31 | $81.25K 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$743.88K derived: sum of 2 quarters · filed 2016-03-14 | -$743.88K derived: sum of 3 quarters · filed 2016-03-14 | $8.00K 10-K · filed 2016-03-14 | |
| 2013-09-30 | -$747.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$747.88K derived: sum of 2 quarters · filed 2014-11-10 | $4.00K 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $751.88K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $751.88K 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $17.00K 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |